Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03806842
Other study ID # FXUSA2018-01
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date November 28, 2018
Est. completion date December 28, 2024

Study information

Verified date September 2023
Source FX Shoulder Solutions
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to collect data to demonstrate the safety and effectiveness of the Easytech Reversed Shoulder System for the treatment of patients who require a reverse total shoulder arthroplasty.


Description:

The clinical study will enroll patient who require a reverse total shoulder arthroplasty as a result of osteoarthritis, post-traumatic arthritis, avascular necrosis and have a massive and non-repairable rotator cuff tear and a functional deltoid muscle. If patients meet the eligibility criteria, evaluations and x-rays will be completed pre-operatively and post-operatively out to 24 months.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 90
Est. completion date December 28, 2024
Est. primary completion date December 28, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: 1. Patients are 21 years or older. 2. Patients are skeletally mature as evident by scapula and proximal humerus closure. 3. Patients exhibit clinical indications for primary reverse total shoulder arthroplasty based on physical exam and medical history including the following: osteoarthritis, post-traumatic arthritis, or avascular necrosis. 4. Patients have a massive and non-repairable rotator cuff tear. 5. Patients have a functional deltoid muscle. 6. Patients are anatomically and structurally suited to receive the implants; a. Subject show sufficient bone quality in the humerus bone intraoperatively via the thumb test, guide pin test, humeral punch test, and humeral anchor test as outlined in the surgical technique. 7. Patients with an adjusted Constant Score < 60 and = 15. 8. Patients are willing and able to comply with the follow-up schedule and evaluation outlined in the protocol. 9. Patient are willing and able to sign the informed consent. Exclusion Criteria: 1. Patients with Body Mass Index (BMI) greater than 40 kg/m2. 2. Patients have one of the following compromising the affected limb: a significant injury to the upper brachial plexus, paralysis of the axillary nerve or a neuromuscular disease compromising the affected limb which would render the procedure unjustifiable. 3. Patients have marked bone loss that would not allow sufficient support of the implant. 4. Patients have a known sensitivity or allergic reaction to one or more of the implanted materials. 5. Patients who are participating concurrently in another clinical study, or have participated in a clinical study within the last 90 days, or intend to during the course of the study. 6. Patients who have an active systemic infection, or an active local infection in or near the target shoulder, or have a previous history of joint infection. 7. Patients with known immunodeficiency. 8. Patients currently taking > 5mg/day corticosteroids (e.g. prednisone) excluding inhalers, within 3 months prior to surgery. 9. Patients with significant comorbidities as evident by an American Society of Anesthesiologists (ASA) score greater than 3. 10. Patients with active neoplastic disease. 11. Patients with current drug or alcohol abuse, or a history of the same within the last 6 months. 12. Patients with local circulatory problems, (e.g. thrombophlebitis and lymphedema). 13. Patients are pregnant or expect to become pregnant during the duration of the study. 14. Patients with any mental or psychological disorder that would impair their ability to complete the study questionnaires. 15. Patients with any medical condition or other circumstances that might interfere with their ability to return for follow-up visits in the judgment of the Investigator, including any systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the patient unable to perform appropriate postoperative rehabilitation. 16. Any condition which, in the judgment of the Investigator, would preclude adequate evaluation of device's safety and performance. 17. Patients with humeral or glenoid fractures. 18. Patients unable to stand from sitting position without the use of their hands/arms. 19. Patients with a history of fragility fractures as defined as any fall from a standing height or less, that results in a fracture. 20. Patients with osteoporosis, osteopenia, Paget's disease, osteomalacia or any other metabolic bone disease; a. Osteoporosis is defined as Simple Calculated Osteoporosis Risk Estimation (SCORE) above 6 and DXA (Dual-energy X-ray absorptiometry) T-score < -2.5 or QCT (Quantitative computed tomography) T-score < 80mg/cubic cm. History of a fragility fracture requires that a DXA scan or QCT scan is completed.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Easytech group
total shoulder replacement

Locations

Country Name City State
United States Texas Orthopedic Specialists Bedford Texas
United States Carrell Clinic Dallas Texas
United States Dearborn & Associates Institute for Joint Reconstruction Menlo Park California
United States University of Pennsylvania Philadelphia Pennsylvania
United States The CORE Institute Sun City West Arizona
United States Orthopedics Rhode Island Wakefield Rhode Island

Sponsors (1)

Lead Sponsor Collaborator
FX Shoulder Solutions

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adjusted Constant-Murley Score adjusted Constant Score of 70 or greater, no humeral radiolucency >2mm or humeral migration/subsidence >5mm, no revision surgery, no serious device related adverse event 24 months post-operative
Primary no humeral radiolucency >2mm around the humeral component on review of x-rays, there are no radiolucencies >2mm around the humeral component 24 months post-operative
Primary no subsidence or migration of the humeral component >5mm on review of x-rays, there is no subsidence or migration of the humeral component greater than or equal to 5mm 24 months post-operative
Primary no revision there is no revision of the humeral components 24 months post-operative
Primary no serious device related adverse event there is no serious device related adverse event reported 24 months post-operative
Secondary QuickDASH measures the ability to complete tasks, absorb forces and severity of symptoms 24 months post-operative
Secondary Visual Analog Scale for Pain (VAS) on 100 point scale where 0 is no pain and 100 is severe pain 24 months post-operative
Secondary American Shoulder and Elbow Surgeon (ASES) patient-reported outcomes with questions on function and pain 24 months post-operative
Secondary Range of Motion of the shoulder joint forward and lateral elevation, internal & external rotation arm at side 24 months
See also
  Status Clinical Trial Phase
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03663036 - Arthroscopic Superior Capsular Reconstruction With Fascia Lata Autograft - Survivorship of the Autograft Analysis N/A
Suspended NCT03290196 - The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics Phase 4
Active, not recruiting NCT03091075 - Oxandrolone Rotator Cuff Trial N/A
Completed NCT03380533 - Buprenorphine Transdermal Patches in Arthroscopic Rotator Cuff Repair Phase 2/Phase 3
Completed NCT04566939 - A Long Term Follow-Up of Rotator Cuff Tear Patients Treated With Integrated Complementary and Alternative Medicine
Active, not recruiting NCT02716441 - Rotator Cuff Failure With Continuity
Completed NCT03540030 - Opioid-Free Shoulder Arthroplasty Phase 4
Completed NCT02298023 - Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells (Rotator Cuff Tear) Phase 2
Completed NCT01383239 - Impact of Postoperative Management on Outcomes and Healing of Rotator Cuff Repairs N/A
Completed NCT01459536 - Assessment of Muscle Function and Size in Older Adults With Rotator Cuff Tear N/A
Completed NCT02850211 - A Selective COX-2 Inhibitor Provides Pain Control But Hinders Healing Following Arthroscopic Rotator Cuff Repair Phase 4
Completed NCT01170312 - Arthroscopic Surgery and Platelet Rich Plasma In Rotator Cuff Tear Evaluation N/A
Completed NCT01204606 - Arthroscopic Rotator Cuff Repair With Multimodal Analgesia(MMA) N/A
Terminated NCT00936559 - Study Evaluating Safety Of BMP-655/ACS As An Adjuvant Therapy For Rotator Cuff Repair Phase 1
Completed NCT00852657 - Comparison of Tendon Repair and Physiotherapy in the Treatment of Small and Medium-sized Tears of the Rotator Cuff N/A
Active, not recruiting NCT00182299 - An RCT to Compare the Outcomes of Patients With Large Rotator Cuff Repair That Undergo Repair With or Without SIS Phase 4
Recruiting NCT06120998 - Quality of Life After Arthroscopic Rotator Cuff Repair
Completed NCT05897866 - Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management (HSSM) N/A
Completed NCT02644564 - Early Clinical Examination and Ultrasonography Screening of Acute Soft Tissue Shoulder Injuries N/A

External Links